Sponsors still put “Argentina” on one regulatory Gantt with a single 90-day bar. That is the mistake. A first-in-human (FIH) or early feasibility study (EFS) for a medical device in Argentina runs as an ANMAT clinical-investigation file plus independent ethics and, where required, provincial oversight. Putting the same Class III implantable on the Argentine market later is a commercial registro under the live holder/HELENA checklist. Same agency name. Different petition, different importer, different success criterion.
If the board slide says “ANMAT approved,” ask which ANMAT. Trial authorization is not a selling license. Do not put both on one Gantt labeled “Argentina.”
Two files, one agency
ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) is Argentina’s national authority for medicines, medical devices, and clinical research. It authorizes clinical investigations for devices used in-country. Ethics sits with an independent ethics committee under ISO 14155 and the Declaration of Helsinki, with provincial jurisdictions such as Buenos Aires providing additional oversight. Those are gates on the trial track, not a commercial license.
For a U.S.-based medtech sponsor, the practical split looks like this:
- Trial file: protocol, investigator brochure, informed consent in Spanish, independent ethics package, provincial filings where they apply, investigational labeling, ISO 14155 monitoring plan, and the import story for units that will only be used in the study. The Argentina clinical-trials hub already publishes a 90-business-day statutory review target; the clock pauses for RFIs, and FIH/EFS device studies often exceed that target. Treat 90 business days as a planning framework, not a guaranteed total start-up time.
- Registro file: commercial sanitary registration for Classes I–IV under Disposición ANMAT N° 64/2025, including the simplified declaración jurada (DDJJ) route for CE-marked Class I/II through HELENA, with a local authorized representative / Technical Director ANMAT will treat as responsible for that certificate. The live ANMAT medical-device registration checklist is the commercial map. It is not a first-in-human permit.
Argentina is a strict single-IoR example on the commercial track (AAR under Disp. 64/2025), already stated on the Ecuador single-IoR sibling post. That holder conversation belongs on market access. It does not clear investigational freight for a FIH.
This site does not publish ANMAT as PAHO/WHO Level 4, and it does not invent an ICH-member claim. Headline ~30% lower versus typical US/EU programs is experience since 2010, not a formal study. None of those facts convert a trial authorization into a registro.
What FDA reviewers will ask later
If the Argentina FIH is meant to support a U.S. IDE or marketing file, design the investigation so the evidence room can satisfy 21 CFR § 812.28 (acceptance of data from clinical investigations conducted outside the United States). That regulation expects GCP, independent ethics review, and a device comparable to the version you will put in front of FDA.
ISO 14155 is the device GCP bridge FDA has publicly recognized for foreign investigations. A clean ANMAT investigation letter does not replace an inspectable trial master file. Keep device accountability, deviation logs, monitoring reports, ethics correspondence, and provincial letters in one place from day one. Eligibility of foreign data under 812.28 is not a clearance prediction.
File the federal, ethics, and provincial packages in parallel when the study design allows it. Sequential filing adds calendar time the statutory 90-business-day target never promised to absorb. Do not put a single “Argentina clock” on the Gantt and call it done.
Import: investigational units are not the registro SKU
A commercial ANMAT registration number does not clear investigational kits. Do not put a cousin SKU’s registro on the airway bill “because the PI knows customs.” Name the trial importer before ethics stamps the protocol. Map every investigational model, accessory, and spare to the investigation-authorized list. Outer labels must read as investigational, with lot or serial traceability that matches the accountability log at the site.
After last patient, close investigational inventory under the trial rules. Leaving units “for the hospital” without a new sanitary path is a new regulatory event, not a courtesy. The commercial HELENA / Class I–IV track — when you actually need it — is a separate workstream with its own importer and its own authorized representative.
Holder vs distributor (commercial track only)
When you later want Argentine market access, ANMAT will look for a local face on the sanitary registration: the authorized representative / Technical Director, renewals, variations, labeling, and vigilance. A distributor who only sells stock is not automatically that holder. Argentina’s single-IoR posture makes that point sharper, not softer. If the holder relationship breaks, the registro does not quietly follow the freight forwarder — you re-file.
The market-access hub already describes ANMAT as risk-based Classes I–IV: lower-risk sworn declaration through HELENA, higher-risk several months on an experience-based clock that is not a statutory cap. Do not collapse that commercial clock into the trial 90-business-day target. Running them as one “Argentina regulatory” workstream is how teams discover, mid-enrollment, that nobody can import the commercial launch SKU.
One-page gate before first patient in Argentina
Write these lines with owners and document IDs before you book site initiation:
- Authority map. ANMAT investigation plus independent ethics (and provincial oversight where required) for the study. Commercial registro under Disp. 64/2025 / HELENA only if a parallel market-access file is truly in scope this year.
- Ethics + investigation sequence. Same protocol version and the same Spanish informed-consent text across federal, ethics, and provincial packages. Plan for RFI pauses on the 90-business-day statutory target.
- Investigational importer. Legal name and the document that ties the shipment to the investigation authorization — not a commercial registro number and not a HELENA DDJJ reference.
- Device list. Every unit that will sit in the site accountability log, including accessories.
- ISO 14155 file owner. Who can produce monitoring, accountability, and ethics letters within 48 hours if FDA or a notified body asks.
- Commercial holder (optional, separate). If launch is real, name the Argentine authorized representative / Technical Director and keep that file off the FIH critical path until first patient is locked.
Where teams burn weeks
Three patterns show up repeatedly on Argentina device files:
- One 90-day bar for both desks. Treating the statutory trial review target as if it also covered Classes I–IV commercial registration. The checklist is a second file. Higher-risk commercial work often runs several months on experience, not on the trial clock.
- Registro number on investigational freight. Using a commercial ANMAT certificate for a predicate or related model to move FIH units. The investigational article is not that registered product.
- One Spanish translation for both desks. The informed-consent and brochure language for ethics and the investigation is not the commercial IFU ANMAT will later lock on a registro. Mixing them creates labeling debt on both tracks.
Fix the patterns on paper before translators start. Re-translation after first patient is a protocol amendment problem, not a word-processing problem. The CRO in Argentina category page and the registration checklist already keep trial and registro apart — keep your Gantt the same way.
Practical next step
This week, split the Argentina slide into two columns: ANMAT investigation and ANMAT registro. If the same person owns both without two dossiers, two importers, and two success criteria, you do not have an Argentina plan — you have a hope. bioaccess® runs FIH/EFS execution across Latin America, including Argentina from Miami, and holds LATAM registration/IOR work as a separate market-access track; treat Argentina the same way inside your own team. Start from the clinical-trials hub for the investigation column and the ANMAT checklist for the registro column — and do not collapse them because both say ANMAT.